Navigation Links
Liver an Excellent Target For Cancer Gene Therapy

A study demonstrates that cancer cells in the liver are excellent targets for gene therapy using adenoviral vectors//. It is based upon a fundamental new understanding of the differences between cancerous and normal liver cells. The findings signal a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast.

The research team, led by Tony Reid, M.D., Ph.D., of the Moores Cancer Center at University of California, San Diego (UCSD), reports that in normal liver cells there is only one receptor – or doorway the vector uses to enter the cell. This doorway is located at the base of normal liver cells, hidden from the blood vessels. The research also demonstrates that in cancerous cells the receptor for adenovirus, called the coxsackie-adenoviral receptor or CAR, is expressed randomly over the surface of the cell and is exposed to the blood vessels.

“Since the receptor is distributed randomly on the surface of tumor cells, the doorway is open for the adenoviral vectors circulating in the blood stream to infect and kill these cells,” said Reid, who was at Stanford University when this work was conducted. “At the same time, normal liver cells are protected. These findings may signal a new way to treat any cancer that has spread to the liver.”

Reid explained: “We are taking advantage of a fundamental characteristic of cancer cells – structural disorganization. The disorganized structure of the cancer cells exposes the receptors so that Onyx-015, the adenoviral vectors used in this study, can readily enter tumor cells. This may be the first time a therapy has been directed against the disorganized nature of cancer cells.”

Reid and his colleagues undertook this study following the death of Jesse Gelsinger, a participant in a gene therapy clinical trial at University of Pennsylvania for ornithine transcarbanoylase (OTC) deficiency, a metabolic liver disorder. That case virtually sto pped gene therapy research and spawned widespread safety concerns about gene therapy involving the liver.

“At that time, I was treating patients with colon cancer that had spread to the liver using a very similar adenoviral vector administered in exactly the same way – direct infusion into the main artery feeding the liver,” said Reid, who is now an associate professor of clinical medicine in the UCSD School of Medicine. “We saw virtually no problems with toxicity in 35 study participants who received a total of nearly 200 infusions across several study sites.”

So Reid and colleagues carefully re-analyzed the data from the 17 participants from the Stanford site to determine the impact of repeated adenoviral exposure on liver function, and documented that there were no significant problems. While the analysis was not designed to demonstrate impact on disease, it showed that seven of the 17 patients had stable-to-improving disease at the completion of four viral infusions. The researchers then demonstrated that normal liver cells could not be infected with an adenovirus, which led them to investigate where the receptor was located. They found it hiding at the junction between liver cells and proved that it was inaccessible from the blood flow in the liver. From there they showed that cancer cells had lost structural polarity, resulting in random distribution of CAR receptors on their surface, thereby allowing the virus to attach to and infect the tumor cells.

“In the process of proving that liver toxicity is not an issue in gene therapy, we have also shown that cancer cells metastatic to the liver are a perfect target for gene therapy because the cancer cells, but not the normal liver cells, are infected by the adenoviral vector,” said Reid. “We also found that other cancer cells, including those from the breast, pancreas and prostate, are readily infected by adenoviral vectors indicating disorganized expression of the CAR receptor in these tumor cells. We believe these findings may have important implications across several types of cancer.”

SourceNewswise
SRM
'"/>




Related medicine news :

1. Blood Cells Capable of Regenerating Liver
2. Liver donors can thrive after transplant
3. Heavy Drinking Raises Risk of Liver Cancer
4. Arthritis Drug May Cause Liver Damage
5. Liver transplant oversight urged
6. Liver key to extending life
7. Liver cancers which spread are linked to a particular gene
8. Liver diseases: The enemy with an accomplice
9. Troubled Childhood found to affect your Liver
10. New Liver Tumor Treatment
11. Transplants Help Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health care ... of Sun Health Senior Living (SHSL) may not share those same worries ... prescription copays for the year, while holding the line on increasing their contributions, including ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... Cypress, Texas (PRWEB) , ... May 26, 2016 , ... ... on Friday, May 13 at Blackhorse Golf Club in Cypress. With the help of ... a non-profit that restores, empowers, and renews hope for wounded service members and their ...
(Date:5/26/2016)... ... ... The MIAMI Institute for Age Management and Intervention celebrates Global Wellness Day with ... Adonis , Wellness Physician of the MIAMI Institute is certified by the American Academy ... , He also heads up FITTLab, the comprehensive medical testing lab located in The ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , ... a bunionette) treatment was more than humbled by customer demand over the Mother’s Day ... SKU's mid sale. Now that Bunion Bootie has completely replenished its inventory levels, it ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
(Date:5/23/2016)... Global Paclitaxel Market 2016 Industry ... companies and the Paclitaxel analysis in this study is ... and its players. This is the latest ... the current state of the industry while providing a ... and industry chain structure. The Paclitaxel market analysis is ...
Breaking Medicine Technology: